Ameren Corp (AEE) Stock Price & Analysis

Ameren Corp (AEE) rose 1.49% to USD 107.99 as of June 9, 2026 at 22:36 UTC, according to Nexqual real-time market data.

AEE last closed at USD 106.4; the session ranged USD 106.14–108.58 on volume of 943,142 shares. Market capitalization is $29.89B, with a 52-week range of USD 93.5–115.59 (NYQ). Source: Nexqual, June 9, 2026 at 22:36 UTC.

Key Statistics (as of June 9, 2026 at 22:36 UTC)

PriceUSD 107.99
Change▲ 1.49% (up)
Previous CloseUSD 106.4
OpenUSD 106.89
Day RangeUSD 106.14 – 108.58
52-Week RangeUSD 93.5 – 115.59
Volume943,142 shares
Market Cap$29.89B
ExchangeNYQ

Technical Analysis (AEE)

Nexqual's technical model rates AEE "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 22:36 UTC.

Overall SignalSTRONG SELL
RSI (14)48.63 (neutral)
vs SMA50Below (USD 110.24)
MACD-0.76 (negative)

Analyst Ratings (AEE)

Wall Street analysts rate AEE "Buy" based on 15 analysts, with a mean price target of USD 119.87 (range USD 105–136), per Nexqual as of June 9, 2026 at 22:36 UTC.

Consensus RatingBuy
Analyst Count15
Mean TargetUSD 119.87
High TargetUSD 136
Low TargetUSD 105
Buy / Hold / Sell10 / 7 / 0

Earnings (AEE)

Next Earnings Date2026-07-30
EPS EstimateUSD 1.08
Revenue Estimate$2.29B

Recent Earnings History

QuarterActual vs Estimate
2026-03-31USD 1.28 vs est 1.17 ▲ beat
2025-12-31USD 0.92 vs est 0.69 ▲ beat
2025-09-30USD 2.35 vs est 2.12 ▲ beat
2025-06-30USD 1.01 vs est 0.99 ▲ beat

Source: Nexqual, June 9, 2026 at 22:36 UTC.

Financials & Fundamentals (AEE)

Total Revenue$8.54B
Revenue Growth (YoY)+3.70%
Gross Margin+50.45%
Operating Margin+27.79%
Profit Margin+17.83%
ROE+11.75%
Debt / Equity155.67
Current Ratio0.62
Total Cash$13.00M
Total Debt$21.30B
Free Cash Flow$-1.87B

Source: Nexqual, June 9, 2026 at 22:36 UTC.

Financial Health Score (AEE)

Nexqual rates Ameren Corp's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 22:36 UTC.

GrowthStrong — Revenue +15% YoY (annual)
ProfitabilityStrong — Gross margin 50%, operating 28%
Balance SheetCritical — $13M cash vs $21.3B debt
Cash FlowWeak — FCF negative: -$1.87B, burning cash
EfficiencyMixed — ROE 12%, ROA 3.1%

Ownership (AEE)

Insider Ownership+0.31%
Institutional Ownership+86.33%
Shares Outstanding276.75M
Float275.43M
Short % of Float+4.03%

Source: Nexqual, June 9, 2026 at 22:36 UTC.

Leadership (AEE)

Ameren Corp is led by Martin J. Lyons (age 58), President, CEO & Chairman of the Board, per Nexqual as of June 9, 2026 at 22:36 UTC.

President, CEO & Chairman of the BoardMartin J. Lyons (age 58)
Executive VP & CFOLeonard P. Singh (age 55)
Group President of Ameren UtilitiesMichael L. Moehn (age 55)
Chairman & President of Ameren Transmission Company of IllinoisShawn E. Schukar (age 63)
Senior Director of Investor Relations & Corporate ModelingAndrew Kirk

Major Backers & Investors (AEE)

Notable institutional backers of Ameren Corp include Price (T.Rowe) Associates Inc, T. Rowe Price, Ameriprise Financial, Inc., according to Nexqual as of June 9, 2026 at 22:36 UTC.

Active Investors

InvestorStake
Price (T.Rowe) Associates Inc9.1%
T. Rowe Price4.26%
Ameriprise Financial, Inc.2.27%
Franklin Resources, Inc.2.05%
Janus Henderson Group PLC1.94%
SELECT SECTOR SPDR TRUST-State Street Utilities Select Sector SPDR ETF1.66%

Index Funds (Passive)

FundStake
Vanguard Group20.07%
BlackRock9.89%
State Street6.58%
Geode Capital2.77%

Source: Nexqual, June 9, 2026 at 22:36 UTC.

From Ameren Corp's Latest SEC 10-K Filing (filed 2026-02-18)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
DTEDTE Energy CompanyUSD 145.95▲ 0.12%
CMSCMS Energy CorporationUSD 72.63▲ 0.82%
AJGArthur J. Gallagher & Co.USD 217.05▲ 0.42%
ETREntergy CorporationUSD 109.66▼ 0.98%
CNPCenterPoint Energy, Inc (HoldinUSD 42.39▼ 0.7%

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:36 UTC. This page is informational and not investment advice.